

# Isolated Langerhans Histiocytosis in Thyroid: Thyroidectomy or Chemotherapy?

ANOOP ATAKKIL<sup>1</sup>, VANDANA THORAWADE<sup>2</sup>, MOHAN JAGADE<sup>3</sup>, RAJESH KAR<sup>4</sup>, KARTIK PARELKAR<sup>5</sup>

## ABSTRACT

Langerhans cell histiocytosis (LCH) is a rare disorder of mononuclear phagocytic system whose clinical presentation varies from the localised involvement of a single bone to a widely disseminated disease. Langerhans cell histiocytosis rarely involves the thyroid gland and isolated involvement of thyroid is even rarer. We report a case of an eight-year-old male child diagnosed with Langerhans cell histiocytosis limited to thyroid gland with review of literature. Should thyroidectomy be done or proceed with chemotherapy? Our case report raises this question with a note on the role of 18 fluoro deoxy glucose positron emission tomography-computed tomography in the management of the same.

## CASE REPORT

An eight-year-old male child with thyroid swelling of six months duration was referred to the Department of ENT & Head and neck surgery, Grant Govt. Medical College, Mumbai, as papillary carcinoma of thyroid was suspected on fine needle aspiration cytology (FNAC). On clinical examination, an anterior neck swelling of size 3x1cm was present, which was firm, non tender, moving with deglutition. There was no voice change or dysphagia. He had no history suggestive of hypo or hyperthyroidism and thyroid function tests were normal. Ultrasound examination of neck revealed enlarged lobes of thyroid bilaterally showing multiple well defined hypo echoic lesion within. Few enlarged necrotic cervical lymph nodes were present bilaterally. An expert review of the FNAC slide was done which was inconclusive. Biopsy of thyroid gland was obtained through a horizontal incision over anterior part of the neck from the left lobe of thyroid. Histopathological examination revealed that the thyroid tissue is replaced in most areas by a diffuse infiltrate of mononuclear cells admixed with lymphocyte and eosinophils [Table/Fig-1]. The mononuclear cells showed bean shaped nucleus with nuclear grooves and moderate pale eosinophilic cytoplasm [Table/Fig-2]. Immunohistochemistry showed those cells expressed CD 1a [Table/Fig-3] and S-100 protein [Table/Fig-4] and were immune negative for CD30 and cytokeratin confirmatory for LCH.

Patient was further evaluated for systemic involvement for LCH. Clinical examination, biochemical and routine blood tests were normal. Antithyroid antibodies and antimicrobial antibodies were within normal limits. In bone marrow examination, there

**Keywords:** CD1a, 18 FDG PET CT, S-100, Thyroid swelling


was no evidence of myelofibrosis, increased histiocytosis or haemophagocytosis [Table/Fig-5].

Ultrasonography of abdomen with skeletal survey were done and found to be normal. An 18FDG PET CT scan whole body was done to detect the systemic involvement which showed active disease in the multiple coalesced hypodense nodules involving both the lobes of the enlarged thyroid [Table/Fig-6]. Hyper metabolic bilateral level 2, 3 and 5 lymph nodes were seen with no active disease elsewhere in the body.


Patient was started on intravenous vinblastine (6mg/m<sup>2</sup>) with oral prednisolone once a week for six weeks. A repeated 18FDG-PET CT scan showed significant reduction in significant decrease in size and metabolic activity of the multiple coalesced hypodense nodules in both lobes of thyroid. Patient was continued on injection vinblastine once every three weekly till one year. His thyroid function was within normal limits throughout the treatment. The thyroid swelling gradually reduced over the course of the treatment and was undetectable at the end of the same. An 18FDG-PET CT done after one year showed absence of any significant disease in thyroid or elsewhere in the body. He tolerated chemotherapy well and is on regular follow up for last one year.

## DISCUSSION

Langerhans cell histiocytosis (LCH) is a neoplastic proliferation of Langerhans cells, with expression of CD1a, S-100 protein and the presence of Birbeck granules by ultrastructural examination [1,2]. The annual incidence has been estimated to be 4 per million and



**[Table/Fig-1]:** Photomicrographs of a low power image showing the thyroid tissue replaced by a diffuse infiltrate of mononuclear cells admixed with lymphocyte and eosinophils. (H&E staining -100 X) **[Table/Fig-2]:** The mononuclear cells shows bean shaped nucleus with nuclear grooves and moderate pale eosinophilic cytoplasm (H&E staining -400X) **[Table/Fig-3]:** Langerhans cells highlighted by CD1a immunostain, showing cytoplasmic staining (-400X)



**[Table/Fig-4]:** Langerhans cells highlighted by S-100 protein immunostain (-400X)

there seems to be a slight predominance of cases in males [3]. The median age at diagnosis for all disease variants is 2 to 3 years [3]. LCH can present along a continuum of illness, ranging from indolent to explosive disease [3]. More frequently affected are the bone (80%), the skin (33%), and the pituitary (25%) followed by the liver, spleen, the hematopoietic system and the lungs (15% each). Finally, the lymph nodes (5-10%) and the central nervous system excluding the pituitary (2-4%) are the other possible localization sites of the disease.

Current literature documents 75 cases of LCH involving the thyroid gland where only 23 cases reported the isolated thyroid involvement in English literature [3]. The thyroid involvement of LCH is more reported in adults than children (47 adult vs 18 paediatric cases) with slight female predilection (1.4:1). LCH cases involving the thyroid gland present with diffuse (39/66 cases) or nodular thyroid (17/66) enlargement [3]. These cases were euthyroid (40.9%) or hypothyroid (19.7%) with less incidence of subclinical hypothyroidism or hyperthyroidism (10.6% vs. 1.5%, respectively) [3].

In a case of thyromegaly, ultrasonography and FNAC needs to be done as a part of preliminary evaluation. In the thyroid, LCH had been mistaken for poorly differentiated carcinoma on histology [4] or lymphocytic thyroiditis or papillary carcinoma on fine-needle aspiration as in our case [5]. They have been diagnosed as LCH retrospectively, following haemithyroidectomy or total thyroidectomy, either diagnostic or curative, for other suspected clinical entities like medullary carcinoma or adenoma [3,6]. In present case FNAC was inconclusive, so the core biopsy was obtained that surgery can be reserved after obtaining the definite pathological diagnosis, considering the age of the child.


The diagnosis of LCH is confirmed on the detection of Langerhans cell whose nuclei are folded or grooved resembling a coffee bean or lobulated and indented akin to those described in our patient. There may be eosinophils, lymphocytes, neutrophils and plasma cells around these cells some times in large number. The definitive diagnosis requires positive staining of the lesional cells with CD1a and S-100 protein on immunohistochemistry [7].

Systemic involvement is evaluated based on blood counts, total protein, Albumin, Bilirubin, ALT, AST, Alkaline phosphatase, BUN-blood urea nitrogen, Creatinine, electrolytes, ESR, abdominal ultrasound, coagulation studies, bone marrow biopsy, chest radiograph and skeletal radiograph survey. In our case, LCH was limited to thyroid gland only which was confirmed by PET scan. Phillips et al., proposed that if a patient has only a single site of disease by plain films and no suspicion of a vertebral lesion PET scans are an excellent screening modality which provide improved sensitivity for locating active or reparative LCH lesions [8]. In the present case, after six cycles of chemotherapy PET scan was done that showed significant decrease in size and metabolic activity of the multiple coalesced hypodense nodules in both lobes of thyroid and draining nodes. The decrease of FDG uptake when treatment

S.No	Parametry	Normal	
1	Total protein	7.8gm/dl	5.9-8.0gm/dL
2	Albumin	4.8 gm/dl	3.7-5.6gm/dL
3	Total Bilirubin	0.9 mg/dL	0.2-1.0 mg/dL
4	ALT (SGPT)	17 IU/L	5-35 IU/L
5	AST (SGOT)	15 IU/L	5-40 IU/L
6	Alkaline phosphatase	140 IU/L	115-345 IU/L
7	INR	1.12	1-1.4
8	APTT	35 s	42-54 sec
9	PT	14s	11-15 sec
10	BUN	12 mg/dl	7-17 mg/dL
11	Creatinine	0.6mg/dL	0.3-0.9mg/dL
12	Na <sup>+</sup> /K <sup>+</sup>	141/ 4.2 mEq/l	Na + 135-148 mEq/L K <sup>+</sup> 3.5-5.8 mEq/L
13	Erythrocyte Sedimentation Rate (ESR)	15 mm/hr	3-20 mm/hr
14	Ca	9.2 mg/dL	9-11 mg/dL
15	Haemoglobin	14.4gm/dL	11.0-13.3gm/dL
16	White blood cell	5400/mm <sup>3</sup>	4500-10500/mm <sup>3</sup>
17	Neutrophils	65%	50-70%
18	Lymphocytes	28%	20-40%
19	Monocytes	5%	2-8%
20	Eosinophils	2%	1-4%
21	Basophils	0	0.5-1%
22	Platelet count	3.5x10 <sup>6</sup> /mm <sup>3</sup>	1.94-3.64 X 10 <sup>6</sup> /mm <sup>3</sup>
23	Free T3	120 ng/dL	96-232 ng/dL
24	Free T4	1.1 ng/dl	0.81-1.68 ng/dL
25	TSH	1.8 mIU/L	0.37-6.00 mIU/L
26	TBG	18 mg/L	15.0-29.2 mg/L
27	Thyroglobulin	15 ug/L	3-42 ug/L
28	Anti thyroid Antibodies	<1.3IU/ml	<35 IU/ml
29	Bone marrow Evaluation	Within normal limits	
30	Abdominal ultrasound	No significant abnormality	
31	FNAC Thyroid	Inconclusive	
32	USG neck	Multiple well defined hypo echoic lesions in both lobes of thyroid gland with a few enlarged necrotic cervical lymph nodes	
33	Biopsy of Thyroid [Table/Fig-2-4]	LCH cells with CD 1a, S-100 Positivity	
34	Skeletal Survey	Within Normal Limits	
35	Contrast-enhanced CT Neck [Table/Fig-6]	A diffusely enlarged thyroid gland with multiple lymph nodes on both side	
36	CT Brain, Chest & Abdomen	Within normal limits	
37	18FDG PET CT scan whole body [Table/Fig-7]	Active disease in the multiple coalesced hypodense nodules involving both the lobes of the enlarged thyroid. Hyper metabolic bilateral level 2, 3 and 5 lymph nodes	

**[Table/Fig-5]:** The diagnostic evaluation done in the child for systemic evaluation

is effective, makes 18FDG PET CT scan the imaging of choice to assess the treatment when compared to other radiographic modalities, especially in soft tissue involvement [8].



**[Table/Fig-6]:** CT Neck with contrast showing the enlarged thyroid with multiple cervical nodes

Should it be thyroidectomy or chemotherapy? The review of literature may suggest resection of LCH by subtotal, near total, or total thyroidectomy is the treatment of choice for localized LCH to the thyroid [6]. 42.4% of the reported cases received surgery for thyroid involvement, 30.3% received surgery and adjuvant chemoradiotherapy, and 18% received chemo-radiotherapy only [3]. Moreover, it is evident that in most of the cases where surgery was suggested, surgery had been done prior to diagnosis and those patients were followed up.

Definitive management in a case where a diagnosis was attained preserving the thyroid gland is still a controversy owing to the lack of prospective randomised studies [9]. One case report proposed thyroidectomy as the treatment but did not rationalise the role of chemotherapy [10]. In the present case expert opinion from the Histiocyte Society was sought for and was advised to proceed with chemotherapy with vinblastine and prednisolone. Thyroid swelling started reducing during the treatment and PET scan done after the complete course showed nil significant active disease within the gland and absence of any new lesions. Only direct RT to the neck would permanently damage the thyroid function. It is possible that

the LCH infiltration might nevertheless damage the thyroid gland, but if the thyroid function is normal before the treatment, there is still a chance to preserve the gland function. He remained euthyroid during and after the course of chemotherapy with no adverse effects. Owing to the rarity and lack of prospective randomised studies, there are limitations in the available clinical data in providing a definitive management protocol.

## CONCLUSION

LCH with solitary involvement of thyroid gland is one of the rarest presentations. The present report signifies the role of chemotherapy and organ preservation in a case of primary LCH thyroid when compared to thyroidectomy. Only a prospective randomized trial can fill the void in the available clinical data that will answer this question and establish the treatment protocols in LCH limited to thyroid.

## REFERENCES

- [1] Henry K. Langerhans cell histiocytosis. In: Barnes L., Eveson J.W., Reichart P., Sidransky D. (Eds): World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours: IARC Press: Lyon 2005: 358.
- [2] Stacy Nicholson. H, Langerhans Cell Histiocytosis. In: Greer JP, Rodgers GM, Foerster J, et al. Wintrobe's Clinical Hematology. 11<sup>th</sup> edition. Philadelphia, USA: Lippincott Williams & Wilkins ;2004: 3681-97
- [3] Patten DK, Wani Z, Tolley N. Solitary Langerhans Histiocytosis of the Thyroid Gland: A Case Report and Literature Review. *Head and Neck Pathol.* 2012;6:279-89.
- [4] Coode PE, Shaikh MU. Histiocytosis X of the thyroid masquerading as thyroid carcinoma. *Hum Pathol.* 1988;19:239-41.
- [5] Kitahama S, Iitaka M, Shimizu T, Serizawa N, Fukasawa N, Miura S, et al. Thyroid involvement by malignant histiocytosis of Langerhans cell type. *Clin Endocrinol.* 1996;45:357-63.
- [6] Vilallonga R, Ciudin A, Fort JM, et al. Isolated Langerhans cell histiocytosis of the thyroid in an adult female: one-year followup. *Int J Endocrinol.* 2011;2011:898302. doi:10.1155/2011/898302.
- [7] Yap WM, et al. Langerhans cell histiocytosis involving the thyroid and parathyroid glands. *Mod Pathol.* 2001;14:111-15.
- [8] Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. *Pediatric blood & cancer.* 2009;52(1):97-101.
- [9] Kevin L, et al. Langerhans cell histiocytosis of the thyroid gland. *American Journal of Otolaryngology.* 2008;29(3):201-04. doi: 10.1016/j.amjoto.2007.05.004.
- [10] Vilallonga R, Ciudin A, Fort JM, et al. Isolated Langerhans Cell Histiocytosis of the Thyroid in an Adult Female: One-Year Follow up. *International Journal of Endocrinology.* 2011;2011:898302. 4 pages, 2011. doi:10.1155/2011/898302.

### PARTICULARS OF CONTRIBUTORS:

1. Junior Resident, Department of E.N.T & Head and Neck Surgery, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India.
2. Assistant Professor and Head of The Unit, Department of E.N.T & Head and Neck Surgery, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India.
3. Professor and Head of The Department, Department of E.N.T & Head and Neck Surgery, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India.
4. Junior Resident, Department of E.N.T & Head and Neck Surgery, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India.
5. Junior Resident, Department of E.N.T & Head and Neck Surgery, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India.

### NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Anoop Attakkil,  
Room No 26, First Floor, ST George Hospital Hostel, Near Cst Station, Mumbai-400001, India.  
E-mail : fasttrack2317@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: **Nov 27, 2014**  
Date of Peer Review: **Mar 18, 2015**  
Date of Acceptance: **Jun 23, 2015**  
Date of Publishing: **Sep 01, 2015**